What guidelines should patients taking neratinib pay special attention to?

Neratinib (Neratinib) is an irreversible pan-ErbB receptor tyrosine kinase inhibitor, mainly used for adjuvant treatment of patients with HER2-positive early breast cancer to reduce the risk of disease recurrence. Since this drug has strong biological activity, patients need to strictly follow medical instructions during use and pay attention to possible adverse reactions. The following are key guidelines to pay special attention to when using neratinib.

1. Usage, dosage and taking time

The recommended dose of neratinib is 240mg (6tablets40mg), taken orally once daily, usually with breakfast. In order to ensure drug absorption, it is recommended to take the drug at the same time every day, and avoid ingesting grapefruit and its products within 2 hours after taking the drug, because grapefruit may affect the metabolism of the drug, causing the drug concentration to increase or decrease, affecting efficacy and safety.

Patients should swallow the tablet whole and do not break, chew or crush it. If you miss a dose, do not make up the dose. Instead, take the next dose at your normal time to avoid overdose. Treatment is usually recommended to last for one year, and the specific course of treatment must be determined by the doctor based on the patient's condition.

2. Preventing and managing diarrhea

Diarrhea is the most common adverse reaction of neratinib, with a high incidence rate, especially in the early stages of treatment. Studies have shown that most patients will experience diarrhea in the first or second week after starting to take the drug. If not controlled, it may lead to dehydration, electrolyte imbalance, and even affect the continuity of treatment. Therefore, patients should prevent and manage diarrhea in advance when taking neratinib.

Preventive measures: Doctors usually recommend that patients start taking anti-diarrhoeal drugs (such as loperamide) at the same time and continue to use them for the first two months, and then gradually reduce the dose according to the situation.

Diarrhea management: If diarrhea is severe (≥3 grade, that is, more than 7 watery stools per day), the medication should be stopped immediately, and the doctor should be consulted to adjust the dose or suspend treatment. Patients should also drink plenty of water, replenish electrolytes, and avoid irritating foods, such as spicy, greasy, or high-fiber foods, to reduce gastrointestinal discomfort.

3. Possible liver toxicity and monitoring

Neratinib may affect liver function, causing liver enzymes (ALT, AST, bilirubin) are elevated, so patients need to regularly monitor liver function during treatment.

Monitoring frequency: During the initial period of medication, doctors usually recommend that patients undergo liver function tests every 2 to 4 weeks, and then adjust the monitoring frequency according to the specific situation.

Criteria for drug discontinuation or dose adjustment: If the patient's liver enzyme levels increase significantly, or symptoms of liver injury such as jaundice, fatigue, darkened urine, etc., the patient should report to the doctor immediately and consider adjusting the dose or suspending the drug.

4. Other precautions and taboos

(1)Drug interactions

Neratinib is mainly metabolized by the CYP3A4 enzyme. Therefore, during use, you should avoid taking it with CYP3A4 strong inhibitors or strong inducers (such as ketoconazole, rifampicin, St. John's wort, etc.) to avoid affecting the efficacy or increasing the risk of adverse reactions.

（2) Fertility and breastfeeding precautions

Pregnant women and women preparing to become pregnant: Neratinib may have a teratogenic risk to the fetus, so pregnant women or women planning pregnancy should avoid using it and take effective contraceptive measures while taking the drug and within 1 months after stopping the drug.

Breastfeeding women: Since the drug may be secreted through breast milk, breastfeeding should be avoided while taking the drug.

(3) Cardiotoxicity monitoring

Neratinib may affect heart function, especially in patients with a history of heart disease. Heart function (LVEF, left ventricular ejection fraction) should be monitored regularly to ensure safety.

Neratinib plays an important role in the adjuvant treatment ofHER2 positive breast cancer, but its adverse reactions (especially diarrhea and liver damage) are relatively common, so it needs to be taken strictly according to the doctor's instructions and the physical condition should be closely monitored. During medication, patients should pay attention to taking medication regularly, preventing diarrhea, checking liver function regularly, and avoid using it at the same time with specific medications. If severe discomfort occurs, you should consult a doctor immediately and adjust the medication plan promptly to ensure the safety and effectiveness of the treatment.

Reference:https://en.wikipedia.org/wiki/Neratinib